RECORLEV® (levoketoconazole) is an investigational cortisol synthesis inhibitor, previously studied in SONICS, and currently being evaluated in LOGICS and OPTICS, phase 3 clinical trials for endogenous Cushing’s syndrome.
The safety and efficacy of RECORLEV (levoketoconazole) for treatment of endogenous Cushing’s syndrome have not been established.
Strongbridge Biopharma sponsored an educational segment about endogenous Cushing’s syndrome on The Balancing Act, “Behind the Mystery: Rare and Genetic Diseases.” The segment features Leslie Edwin, a patient with endogenous Cushing’s syndrome and Director of Support Groups for Cushing’s Support & Research Foundation, and Maria Fleseriu, MD, Professor/Director at the Pituitary Center at Oregon Health and Science University (OHSU). A broad range of topics related to Cushing’s syndrome are addressed within the segment, including symptoms, misdiagnosis, the importance of seeing an endocrinologist, screening methods, treatment options, and research efforts that are underway.
*Based on proprietary Strongbridge Biopharma plc market research.
© 2020 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Dublin Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
MLR-0010 V17 02/2020